Bristol-Myers Squibb Co. said FDA has accepted for Priority Review its Biologics License Application for lisocabtagene maraleucel (liso-cel), the company’s autologous anti-CD19 CAR T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The FDA has set a Prescription Drug User Fee Act goal date of Aug. 17.
In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.
